TARRYTOWN, N.Y., Dec. 20, 2019 /PRNewswire/ -- Regeneron
Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its
presentation at the 38th Annual J.P. Morgan Healthcare
Conference on Monday, January 13,
2020. The presentation is scheduled for 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time) and may be accessed from
the "Investors & Media" page of Regeneron's website at
http://investor.regeneron.com/events.cfm. A breakout session
will immediately follow the formal presentation and can also be
accessed from our website. An archived version of the
presentation and the breakout session will be available for at
least 30 days.
Following the announcement regarding the Intent to Restructure
the Antibody Collaboration for Kevzara® (sarilumab) and Praluent®
(alirocumab) with Sanofi, Regeneron will provide financial guidance
for 2020 at a date subsequent to the J.P. Morgan Healthcare
Conference.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading
biotechnology company that invents life-transforming medicines for
people with serious diseases. Founded and led for 30 years by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to seven
FDA-approved treatments and numerous product candidates in
development, all of which were homegrown in our laboratories. Our
medicines and pipeline are designed to help patients with eye
diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, infectious diseases, pain
and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary
VelociSuite® technologies, including
VelocImmune® which uses a unique
genetically-humanized mouse to produce optimized fully-human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world.
For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
Contact Information:
Investor Relations
Justin Holko
914.847.7786
justin.holko@regeneron.com
Corporate Communications
Hala Mirza
914.847.3422
hala.mirza@regeneron.com
View original
content:http://www.prnewswire.com/news-releases/regeneron-announces-presentation-at-the-38th-annual-jp-morgan-healthcare-conference-300978211.html
SOURCE Regeneron Pharmaceuticals, Inc.